Please assess the completion status of the following clinical trial:

Trial Title: Standardized Treatment of Pulmonary Exacerbations II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Key Inclusion Criteria:~* Male or female ≥18 years of age at Visit 1~* Documentation of a CF diagnosis~* Enrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR) prior to Visit 1 (US sites only)~* At the time of Visit 1, there is a plan to initiate IV antibiotics for a pulmonary exacerbation~* Performed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit 3~* Completed the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire at Visit 3~* Willing to adhere to a specific treatment duration determined by initial response to treatment and subsequent randomization~* Willing to return for follow up Visit 3~* Written informed consent obtained from the subject or subject's legal representative~Exclusion Criteria:~Key Exclusion Criteria~* Previous randomization in this study~* Treatment with IV antibiotics in the 6 weeks prior to Visit 1~* Admission to the intensive care unit for current pulmonary exacerbation in the two weeks prior to Visit 2, unless admission was due to a desensitization protocol~* Pneumothorax in the two weeks prior to Visit 2~* Primary diagnosis for current hospitalization is unrelated to worsening lower respiratory symptoms (e.g., pulmonary clean out, distal intestinal obstruction syndrome (DIOS), sinusitis)~* Massive hemoptysis defined as \> 250 cc in a 24 hour period or 100 cc/day over 4 consecutive days occurring in the two weeks prior to Visit 2~* Current pulmonary exacerbation thought to be due to allergic bronchopulmonary aspergillosis (ABPA)~* At Visit 1, receiving ongoing treatment with a duration of more than 2 weeks with prednisone equivalent to \>10mg/day~* History of solid organ transplantation~* Receiving antimicrobial therapy to treat non-tuberculous mycobacterium (e.g., M. abscessus, M. avium complex) in the two weeks prior to Visit 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ERR-10 (Type: OTHER): ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
- ERR-14 (Type: OTHER): ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
- NERR-14 (Type: OTHER): NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
- NERR-21 (Type: OTHER): NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).